peninsula
approv
antivir
therapi
vaccin
avail
treat
prevent
sever
diseas
associ
rvfv
infect
human
adenosin
analog
galidesivir
broadspectrum
antivir
drug
candid
vitro
antivir
potenc
ec
less
differ
virus
across
eight
differ
viru
famili
report
activ
galidesivir
hamster
model
peracut
rvfv
infect
intramuscular
intraperiton
treatment
effect
limit
system
rvfv
strain
infect
demonstr
significantli
improv
surviv
outcom
absenc
infecti
viru
spleen
major
serum
brain
liver
sampl
collect
infect
anim
find
support
develop
galidesivir
antivir
therapi
use
treat
sever
rvfv
infect
possibl
relat
phlebovir
diseas
rift
valley
fever
viru
rvfv
famili
phenuivirida
genu
phleboviru
mosquitoborn
pathogen
caus
sever
diseas
human
livestock
endem
subsaharan
africa
arabian
peninsula
bird
et
al
infect
human
occur
via
mosquito
bite
exposur
anim
tissu
process
handl
infect
anim
typic
result
rel
mild
febril
ill
howev
small
percentag
case
result
sever
often
fatal
hemorrhag
fever
accompani
retin
fulmin
hepat
enceph
ikegami
makino
mcelroy
nichol
current
approv
vaccin
antivir
prevent
treat
rvfv
infect
kortekaa
viru
also
transmiss
human
via
aerosol
underlin
concern
regard
potenti
use
bioterror
agent
classif
categori
prioriti
pathogen
niaid
addit
world
health
organ
list
rvf
high
prioriti
diseas
public
health
interest
number
arbovir
human
diseas
outbreak
america
caribbean
territori
occur
recent
year
presum
introduct
foreign
virus
global
travel
trade
golnar
et
al
potenti
also
exist
rvfv
spread
outsid
establish
endem
area
due
capac
speci
mosquito
genera
throughout
world
serv
vector
turel
et
al
introduct
viru
anim
human
popul
pose
signific
risk
suscept
speci
agricultur
import
well
public
health
thu
urgent
need
develop
effect
therapeut
vaccin
treat
prevent
rvfv
infect
galidesivir
adenosin
analog
substitut
carbon
nitrogen
posit
base
substitut
nitrogen
oxygen
posit
ribos
ring
warren
et
al
viral
rna
polymeras
substitut
natur
nucleotid
galidesivir
triphosph
structur
chang
alter
electrostat
interact
result
prematur
termin
elong
rna
strand
galidesivir
demonstr
broadspectrum
antivir
activ
wide
rang
virus
includ
filovirus
togavirus
bunyavirus
arenavirus
paramyxovirus
coronavirus
flavivirus
one
orthomyxoviru
one
picornaviru
warren
et
al
current
clinic
develop
antivir
therapi
ebola
viru
diseas
taylor
et
al
pilot
studi
galidesivir
also
shown
confer
partial
protect
mous
model
rvfv
infect
warren
et
al
recent
efficaci
zika
tickborn
flaviviru
infect
model
report
eyer
et
al
juland
et
al
administr
galidesivir
versu
placebo
healthi
subject
recent
conclud
promis
pharmacokinet
properti
good
toler
taylor
et
al
better
defin
antivir
activ
galidesivir
potenti
therapi
rift
valley
fever
rvf
diseas
evalu
pharmacokinet
galidesivir
hamster
evalu
efficaci
compound
multipl
rout
rvfv
hamster
infect
model
find
support
advanc
develop
galidesivir
broadspectrum
therapeut
potenti
applic
rvf
treatment
anim
procedur
compli
usda
guidelin
conduct
aaalacaccredit
facil
utah
state
univers
approv
institut
anim
care
use
committe
femal
syrian
golden
hamster
g
purchas
charl
river
laboratori
wilmington
quarantin
least
h
prior
viru
challeng
drug
administr
molecular
clone
strain
rvfv
obtain
dr
stuart
nichol
cdc
atlanta
ga
viru
stock
plaqueform
unit
pfu
ml
passag
cell
passag
vero
cell
use
clarifi
cell
cultur
lysat
prepar
dilut
steril
minim
essenti
medium
mem
hyclon
logan
ut
inocul
subcutan
sc
inject
ml
contain
pfu
ventral
right
side
abdomen
vaccin
strain
rvfv
obtain
dr
robert
tesh
world
refer
center
emerg
virus
arbovirus
univers
texa
medic
branch
galveston
tx
vitro
experi
strain
conduct
biosafeti
level
facil
work
pathogen
strain
perform
contain
laboratori
galidesivir
provid
biocryst
pharmaceut
inc
durham
nc
ribavirin
icn
pharmaceut
inc
costa
mesa
ca
galidesivir
dilut
phosphatebuff
salin
pb
steril
filter
administr
intramuscular
im
inject
intraperiton
ip
administr
galidesivir
dilut
steril
lactat
ringer
solut
lr
prior
filtrat
ribavirin
prepar
pb
lr
vero
cell
atcc
manassa
va
maintain
mem
supplement
fetal
bovin
serum
fb
vari
concentr
galidesivir
start
serial
dilut
ribavirin
start
serial
dilut
ad
test
well
contain
confluent
vero
cell
mem
contain
fb
gentamycin
time
rvfv
strain
infect
multipl
infect
approxim
toxic
determin
done
parallel
galidesivir
ribavirin
concentr
ad
uninfect
vero
cell
plate
incub
co
day
time
cultur
supernat
collect
endpoint
titrat
infecti
viru
plate
process
assess
cell
viabil
neutral
red
nr
vital
dye
uptak
viru
yield
reduct
vyr
previous
describ
gowen
et
al
effect
concentr
ec
base
cpe
reduct
assay
effect
concentr
ec
concentr
drug
reduc
viru
yield
one
log
determin
regress
analysi
cell
cytotox
dose
cc
determin
nr
dye
uptak
uninfect
drugtreat
cell
select
index
si
valu
calcul
use
formula
si
cc
ec
ec
hamster
weigh
morn
infect
group
averag
weight
per
group
across
entir
experi
vari
less
g
experi
design
shown
tabl
anim
group
n
treatment
group
n
placebo
group
treat
twice
daili
bid
im
inject
differ
dose
regimen
galidesivir
pb
vehicl
placebo
day
load
dose
begin
min
prior
challeng
pfu
rvfv
due
higher
volum
requir
load
dose
inject
administ
ip
follow
im
bid
mainten
dose
ribavirin
mgkgday
ip
includ
posit
comparison
control
four
anim
infect
group
five
placebo
group
design
sacrific
day
postinfect
pi
optim
day
analysi
peak
serum
tissu
viral
titer
scharton
et
al
serum
also
analyz
comprehens
blood
chemistri
paramet
measur
liver
kidney
function
supplement
tabl
remain
anim
observ
day
morbid
mortal
addit
infect
group
noninfect
anim
n
per
group
treat
parallel
shown
tabl
observ
day
assess
drug
toler
hamster
weigh
day
prior
drug
administr
group
achiev
even
weight
distribut
across
experiment
group
studi
design
anim
treatment
group
n
treat
design
concentr
galidesivir
vehicl
placebo
n
ip
inject
shown
experi
design
tabl
three
anim
dosag
group
design
whole
blood
collect
retroorbit
bleed
min
right
eye
use
lithium
heparin
capillari
tube
lithium
heparin
gel
plasma
tube
h
left
eye
termin
bleed
cardiac
punctur
h
posttreat
whole
blood
collect
second
set
anim
treatment
group
min
right
eye
h
left
eye
h
posttreat
cardiac
punctur
anim
treat
lr
vehicl
placebo
bled
min
h
h
time
point
plasma
sampl
process
centrifug
store
prior
shipment
altura
analyt
inc
moscow
id
bioanalysi
pk
analysi
data
individu
data
anim
dosag
group
pool
time
point
surrog
mean
plasma
profil
compil
time
point
dose
mean
plasma
concentr
analyz
noncompartment
analysi
phoenix
winnonlin
v
certara
usa
determin
mean
pk
paramet
dose
group
hamster
weigh
morn
infect
sort
minim
weight
variat
across
experiment
anim
group
experi
design
shown
tabl
anim
group
n
treatment
group
treat
differ
dose
regimen
galidesivir
vehicl
lr
placebo
ip
inject
day
load
dose
select
group
begin
min
prior
rvfv
challeng
ribavirin
mgkgday
includ
posit
control
four
anim
infect
group
design
sacrific
day
pi
analysi
serum
tissu
viral
titer
remain
anim
observ
day
morbid
mortal
viru
titer
assay
use
previous
describ
infecti
cell
cultur
assay
gowen
et
al
briefli
specif
volum
tissu
homogen
serum
serial
dilut
ad
triplic
well
vero
cell
atcc
monolay
microtit
plate
viral
cytopath
effect
cpe
determin
day
plate
endpoint
calcul
describ
reed
muench
lower
limit
detect
log
ccid
ml
serum
log
ccid
g
tissu
upper
limit
detect
log
ccid
ml
serum
g
tissu
respect
sampl
present
viru
outsid
limit
detect
valu
repres
limit
detect
assign
statist
analysi
determin
group
size
primari
outcom
surviv
efficaci
studi
power
analysi
perform
use
commonli
accept
valu
type
error
power
surviv
analyz
accord
method
kaplan
meier
use
mantelcox
logrank
test
oneway
analysi
varianc
anova
dunnett
method
correct
multipl
comparison
use
assess
differ
viru
titer
differ
number
survivor
compoundtr
placebo
group
analyz
fisher
exact
twotail
test
statist
evalu
done
use
prism
graphpad
softwar
la
jolla
ca
vitro
antivir
activ
galidesivir
rvfv
strain
evalu
primari
cpe
reduct
measur
nr
uptak
vyr
assay
cytotox
galidesivir
minim
cc
ec
determin
cpe
reduct
assay
ec
measur
vyr
result
si
valu
respect
galidesivir
ec
ec
valu
previous
report
rvfv
use
assay
base
highcont
imag
analysi
warren
et
al
incorpor
galidesivir
nascent
viral
rna
chain
parent
galidesivir
compound
must
phosphoryl
host
cell
galidesivirtriphosph
galidesivirtp
howev
mani
cell
line
includ
vero
ineffici
anabol
galidesivir
galidesivirtp
result
ec
valu
doubl
digit
micromolar
rang
taylor
et
al
therefor
rel
high
ec
ec
valu
fulli
repres
compound
potenti
vivo
antivir
activ
normal
control
weight
chang
viral
titer
sacrif
day
treatment
initi
min
preinfect
peracut
sever
natur
rvfv
infect
hamster
scharton
et
al
select
treatment
regimen
design
rapidli
achiev
high
concentr
galidesivir
im
rout
select
base
previou
anim
studi
warren
et
al
given
highli
lethal
natur
rvfv
infect
hamster
ip
load
dose
day
infect
includ
accord
tabl
addit
group
challeng
rvfv
five
group
uninfect
anim
n
treat
parallel
assess
drug
toler
unexpectedli
lowest
dose
galidesivir
mgkgday
effect
treatment
parallel
efficaci
observ
posit
control
drug
ribavirin
fig
b
supplement
tabl
anim
treat
higher
dose
drug
lower
surviv
rate
consequ
reduc
drug
toler
mgkgday
dosag
welltoler
fig
anim
treat
vehicl
placebo
succumb
diseas
day
pi
effect
galidesivir
treatment
inhibit
viral
replic
hamster
sacrif
day
pi
shown
fig
rvfv
undetect
serum
spleen
brain
anim
singl
anim
galidesivir
mgkgday
group
detect
viral
load
liver
expect
sampl
anim
treat
ribavirin
also
devoid
viru
dramat
reduct
viral
titer
highli
signific
compar
hamster
treat
pb
placebo
p
serum
collect
day
pi
also
analyz
comprehens
biochemistri
paramet
supplement
tabl
except
decreas
total
protein
albumin
galidesivirtr
anim
blood
chemistri
valu
differ
significantli
compar
shaminfect
normal
control
addit
im
rout
investig
ip
administr
rout
anoth
treatment
model
approxim
intraven
deliveri
rout
recent
studi
hamster
deem
mgkgday
galidesivir
administ
ip
bid
day
maximum
toler
dose
juland
et
al
base
data
analyz
pk
escal
dose
mgkg
galidesivir
solubil
lr
deliv
ip
inject
whole
blood
sampl
collect
multipl
time
point
within
window
follow
administr
shown
tabl
follow
singl
dose
administr
exposur
galidesivir
increas
greater
proport
increas
dose
fig
increas
peak
plasma
concentr
c
max
increas
dose
area
curv
auc
increas
increas
dose
consist
previou
data
obtain
rat
warren
et
al
appear
second
c
max
h
h
base
previou
rat
data
result
like
outcom
rapid
initi
uptak
galidesivir
cell
convers
activ
triphosph
form
drug
follow
slower
catabol
back
fig
efficaci
galidesivir
rvfv
infect
toler
syrian
golden
hamster
experi
surviv
outcom
b
percent
weight
chang
anim
challeng
sc
rvfv
n
treat
bid
indic
load
ip
mainten
im
dose
galidesivir
mgkg
day
placebo
day
accord
tabl
ribavirin
administ
ip
bid
day
c
surviv
outcom
percent
weight
chang
uninfect
anim
n
treat
describ
tabl
assess
toler
galidesivir
treatment
weight
data
repres
group
mean
standard
error
mean
percent
chang
weight
surviv
anim
rel
start
weight
day
p
p
p
compar
anim
receiv
placebo
parent
compound
excret
biphas
kinet
galidesivir
rapid
uptak
cell
convers
activ
moieti
much
slower
excret
reflect
larg
volum
distribut
v
drug
exemplifi
studi
conduct
albino
rat
wistarhan
femal
rat
biocryst
unpublish
data
v
lkg
lkg
respect
base
ip
galidesivir
pk
analysi
data
select
variou
dosag
regimen
without
day
load
dose
second
evalu
rvfv
hamster
infect
model
accord
tabl
group
treat
galidesivir
significantli
improv
surviv
outcom
compar
placebotr
anim
administ
dose
lower
dosedepend
effect
observ
lower
percentag
anim
surviv
infect
mgkgday
treatment
group
compar
mgkgday
dose
group
fig
supplement
tabl
galidesivir
dose
mgkgday
provid
greatest
protect
anim
surviv
uniformli
lethal
rvfv
challeng
notabl
ribavirin
treatment
result
lengthi
delay
time
death
dramat
weight
loss
surviv
fig
supplement
tabl
one
anim
treat
lr
vehicl
placebo
succumb
diseas
day
pi
outlier
expir
day
effect
galidesivir
treatment
reduc
viral
titer
hamster
cohort
sacrif
day
pi
shown
fig
across
tissu
serum
galidesivir
treatment
larg
result
undetect
level
viru
mean
titer
reduc
order
magnitud
dramat
reduct
viral
load
serum
test
tissu
highli
signific
compar
placebo
group
p
notabl
contrast
galidesivirtr
hamster
anim
receiv
ribavirin
found
log
infecti
rvfv
liver
brain
tissu
fig
addit
anim
analyz
day
pi
surviv
anim
day
analyz
endofstudi
rvfv
titer
serum
liver
spleen
brain
viru
found
test
sampl
data
shown
indic
survivor
clear
viral
infect
limit
detect
infecti
titer
assay
use
galidesivir
adenosin
analog
design
block
viral
rna
synthesi
inhibit
rnadepend
rna
polymeras
rdrp
activ
via
nonoblig
rna
chain
termin
warren
et
al
achiev
galidesivir
parent
compound
first
must
convert
galidesivirtriphosph
incorpor
nascent
viral
rna
rdrp
caus
prematur
termin
transcript
viral
rna
via
group
permit
nucleotid
addit
direct
action
viral
rdrp
allow
galidesivir
exert
broadspectrum
antivir
activ
wide
rang
virus
taylor
et
al
galidesivir
shown
amelior
hemorrhag
diseas
manifest
marburg
virusinfect
fig
analysi
day
serum
tissu
viral
titer
rvfvinfect
hamster
treat
galidesivir
efficaci
experi
hamster
treat
describ
tabl
fig
four
placebo
anim
group
design
sacrific
day
pi
analysi
serum
b
liver
c
spleen
brain
viru
titer
uniqu
symbol
treatment
group
repres
valu
anim
across
paramet
xaxi
repres
lower
limit
detect
greyhash
line
indic
assay
upper
limit
detect
one
anim
receiv
highest
dose
galidesivir
succumb
prior
sacrific
thu
includ
analysi
p
compar
anim
receiv
placebo
cynomolgu
macaqu
warren
et
al
could
potenti
valu
indic
involv
lifethreaten
viral
diseas
includ
rvf
expand
preclin
character
vivo
antivir
activ
galidesivir
evalu
lethal
hamster
model
rvfv
infect
antivir
proven
protect
hamster
exquisit
sensit
strain
rvfv
reflect
rapid
uniform
lethal
within
day
challeng
littl
pfu
viru
high
titer
viremia
substanti
viral
load
tissu
examin
scharton
et
al
find
show
galidesivir
abl
significantli
delay
diseas
progress
anim
protect
mortal
due
rapidli
progress
highli
lethal
peracut
natur
rvfvinduc
diseas
hamster
high
level
efficaci
compar
observ
anoth
rdrp
inhibitor
favipiravir
abl
protect
hamster
lethal
rvfv
challeng
treatment
initi
h
pi
scharton
et
al
result
highli
encourag
support
continu
develop
galidesivir
studi
wellcharacter
nonhuman
primat
model
hartman
et
al
smith
et
al
fig
pk
analysi
plasma
sampl
uninfect
hamster
dose
ip
escal
dose
galidesivir
anim
treatment
group
n
treat
mgkg
galidesivir
vehicl
placebo
n
ip
inject
whole
blood
collect
design
time
tabl
arithmet
mean
standard
deviat
plasma
concentr
mean
composit
pk
paramet
tabl
inset
shown
fig
effect
galidesivir
surviv
outcom
b
percent
weight
chang
hamster
challeng
sc
rvfv
efficaci
experi
anim
group
n
treat
indic
load
mainten
dose
galidesivir
mgkgday
ribavirin
placebo
administ
ip
inject
day
accord
tabl
weight
data
repres
group
mean
standard
error
mean
percent
chang
weight
surviv
anim
rel
start
weight
day
p
compar
anim
receiv
placebo
rt
ws
employ
biocryst
pharmaceut
inc
manufactur
galidesivir
author
declar
compet
interest
exist
fig
analysi
day
serum
tissu
viral
titer
rvfvinfect
hamster
treat
galidesivir
efficaci
experi
hamster
treat
describ
tabl
fig
four
anim
per
group
design
sacrific
day
pi
analysi
serum
b
liver
c
spleen
brain
viru
titer
uniqu
symbol
treatment
group
repres
valu
anim
across
paramet
xaxi
repres
lower
limit
detect
greyhash
line
indic
assay
upper
limit
detect
p
compar
anim
receiv
placebo
